JAMA network open

Use of Wearable Devices by People in the US With or at Risk for Heart Disease, 2019–2020

Updated

Abstract

Fewer than 1 in 4 individuals with cardiovascular disease (CVD) in the US use wearable devices.

  • An estimated 3.6 million adults with CVD and 34.5 million adults at risk for CVD use wearable devices, compared to 29% of the overall adult population.
  • Older age, lower educational attainment, and lower household income are associated with lower use of wearable devices among adults at risk for CVD.
  • Among users, 38% of adults with CVD report using wearable devices daily, compared to 49% of the overall population and 48% of those at risk.
  • A significant majority of wearable device users with CVD (83%) and those at risk (81%) are in favor of sharing their data with clinicians to enhance care.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Oikonomou reported receiving personal fees from Evidence2Health and stock options from Caristo Diagnostics and being a coinventor of US Provisional Patent Application 63/177,117 outside the submitted work. Dr Wilson reported receiving grant funding from Whoop Inc, during the conduct of the study and from the National Institute of Diabetes and Digestive and Kidney Diseases, the Agency for Healthcare Research and Quality, AstraZeneca, and Vifor Pharma outside the submitted work. Dr Krumholz reported receiving expenses and/or personal fees from UnitedHealthcare, Element Science, Inc, Aetna Inc, Reality Labs, Tesseract/4 Catalyst, F-Prime, the Siegfried & Jensen law firm, the Arnold & Porter law firm, and the Martin Baughman, PLLC; being a cofounder of Refactor Health and Hugo Health; and being associated with contracts through Yale New Haven Hospital from the Centers for Medicare & Medicaid Services and through Yale University from Johnson & Johnson outside the submitted work. Dr Khera reported receiving grant funding from the National Heart, Lung, and Blood Institute (NHLBI) and the Doris Duke Charitable Foundation during the conduct of the study; personal fees from Evidence2Health, for which he is a cofounder; and grant funding from Bristol-Myers Squibb and Novo Nordisk outside the submitted work and having patents pending for Provisional Applications No. 63/177,117 (Methods for neighborhood phenomapping for clinical trials), No. 63/346,610 (Articles and methods for format independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning), and No. 63/428,569 (Articles and methods for detection of hidden cardiovascular disease from portable electrocardiographic signal data using deep learning). No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free